Dual HER2 inhibition: Is two better than one?

Matthew R Strickland; Samuel J Klempner

doi:10.1016/j.medj.2024.07.008

Dual HER2 inhibition: Is two better than one?

Med. 2024 Oct 11;5(10):1191-1193. doi: 10.1016/j.medj.2024.07.008.

Authors

Matthew R Strickland¹, Samuel J Klempner²

Affiliations

¹ Department of Medicine, Division of Hematology-Oncology, Massachusetts General Cancer Center, Boston, MA, USA.
² Department of Medicine, Division of Hematology-Oncology, Massachusetts General Cancer Center, Boston, MA, USA. Electronic address: [email protected].

PMID: 39395400
DOI: 10.1016/j.medj.2024.07.008

Abstract

Li et al. present data from a randomized frontline phase II trial in HER2+ gastroesophageal cancers exploring dual targeting of HER2 with HLX22 (a novel HER2-specific antibody) with HLX02 (a trastuzumab biosimilar) and capecitabine/oxaliplatin chemotherapy. While the objective response and progression-free survival are encouraging, the future development of the combination in a crowded HER2 space remains unclear.

MeSH terms

Antineoplastic Combined Chemotherapy Protocols* / pharmacology
Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
Capecitabine* / pharmacology
Capecitabine* / therapeutic use
Esophageal Neoplasms / drug therapy
Humans
Oxaliplatin / pharmacology
Oxaliplatin / therapeutic use
Randomized Controlled Trials as Topic
Receptor, ErbB-2* / antagonists & inhibitors
Receptor, ErbB-2* / metabolism
Stomach Neoplasms* / drug therapy
Trastuzumab* / pharmacology
Trastuzumab* / therapeutic use

Substances

Receptor, ErbB-2
Capecitabine
ERBB2 protein, human
Trastuzumab
Oxaliplatin